Rifaximin
12072
Approved small_molecule completed
Quick answer
Rifaximin for Clostridium Difficile Infection is a Approved program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Clostridium Difficile Infection
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed